ECSP21056325A - Compuesto heterocíclico y su uso - Google Patents

Compuesto heterocíclico y su uso

Info

Publication number
ECSP21056325A
ECSP21056325A ECSENADI202156325A ECDI202156325A ECSP21056325A EC SP21056325 A ECSP21056325 A EC SP21056325A EC SENADI202156325 A ECSENADI202156325 A EC SENADI202156325A EC DI202156325 A ECDI202156325 A EC DI202156325A EC SP21056325 A ECSP21056325 A EC SP21056325A
Authority
EC
Ecuador
Prior art keywords
heterocyclic compound
relates
present
receptor agonist
agonist activity
Prior art date
Application number
ECSENADI202156325A
Other languages
English (en)
Inventor
Keisuke Imamura
Norihito Tokunaga
Yuhei Miyanohana
Tatsuki Koike
Takahiro Sugimoto
Kohei Takeuchi
Tsuneo Oda
Yoshiteru Ito
Tohru Miyazaki
Yasushi Hattori
Yuichi Kajita
Alexander Martin Pawliczek
Yasutaka Hoashi
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69770989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP21056325(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of ECSP21056325A publication Critical patent/ECSP21056325A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente invención se refiere a un compuesto heterocíclico, particularmente, un compuesto heterocíclico que tiene una actividad de agonista del receptor de orexina tipo 2
ECSENADI202156325A 2019-01-31 2021-07-30 Compuesto heterocíclico y su uso ECSP21056325A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019015488 2019-01-31

Publications (1)

Publication Number Publication Date
ECSP21056325A true ECSP21056325A (es) 2021-09-30

Family

ID=69770989

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202156325A ECSP21056325A (es) 2019-01-31 2021-07-30 Compuesto heterocíclico y su uso

Country Status (32)

Country Link
US (8) US11028048B2 (es)
EP (2) EP4578853A3 (es)
JP (2) JP7253640B2 (es)
KR (1) KR102882779B1 (es)
CN (6) CN118271297A (es)
AR (1) AR117916A1 (es)
AU (1) AU2020215380B2 (es)
BR (1) BR112021014180A2 (es)
CA (1) CA3124536A1 (es)
CL (1) CL2021001973A1 (es)
CO (1) CO2021011188A2 (es)
DK (1) DK3917616T3 (es)
EA (1) EA202192138A1 (es)
EC (1) ECSP21056325A (es)
ES (1) ES3037650T3 (es)
FI (1) FI3917616T3 (es)
HR (1) HRP20250785T1 (es)
HU (1) HUE071890T2 (es)
IL (1) IL284073B2 (es)
LT (1) LT3917616T (es)
MX (1) MX2021008241A (es)
MY (1) MY209784A (es)
PE (1) PE20211700A1 (es)
PH (1) PH12021551846A1 (es)
PL (1) PL3917616T3 (es)
PT (1) PT3917616T (es)
RS (1) RS67170B1 (es)
SG (1) SG11202106791XA (es)
SI (1) SI3917616T1 (es)
TW (1) TWI832962B (es)
WO (1) WO2020158958A1 (es)
ZA (1) ZA202106304B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10428023B2 (en) * 2017-08-03 2019-10-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
PE20211700A1 (es) 2019-01-31 2021-09-01 Takeda Pharmaceuticals Co Compuesto heterociclico y su uso
KR20260083444A (ko) 2019-11-25 2026-06-05 알케르메스,인코포레이티드 치환된 마크로사이클릭 화합물 및 관련 치료 방법
WO2021106975A1 (ja) 2019-11-27 2021-06-03 武田薬品工業株式会社 複素環化合物
US20230365533A1 (en) 2020-08-18 2023-11-16 Merck Sharp & Dohme Llc Bicycloheptane pyrrolidine orexin receptor agonists
US12503475B2 (en) 2020-09-03 2025-12-23 Centessa Pharmaceuticals (Uk) Limited Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists
CN116635393A (zh) * 2020-09-03 2023-08-22 欧瑞夏治疗有限公司 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途
JP2022064180A (ja) * 2020-10-13 2022-04-25 武田薬品工業株式会社 複素環化合物
WO2022094012A1 (en) 2020-11-02 2022-05-05 Merck Sharp & Dohme Corp. Macrocyclic urea orexin receptor agonists
US12006330B2 (en) 2020-12-21 2024-06-11 Alkermes, Inc. Substituted macrocyclic compounds and related methods of treatment
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
US20240165092A1 (en) 2021-04-02 2024-05-23 Takeda Pharmaceutical Limited Company Use of an orexin 2 receptor agonist for post operation recovery
WO2022207935A1 (en) * 2021-04-02 2022-10-06 Orexia Therapeutics Limited 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists
JP7833486B2 (ja) 2021-05-26 2026-03-19 アルカーメス，インコーポレイテッド 置換されるカルバメート大環状化合物および関連のある治療方法
WO2023167925A1 (en) 2022-03-01 2023-09-07 Orexia Therapeutics Limited Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses
US20250250230A1 (en) 2022-04-12 2025-08-07 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP4600242A1 (en) 2022-10-07 2025-08-13 Kissei Pharmaceutical Co., Ltd. Cyclopentane compound
PE20251923A1 (es) 2022-10-31 2025-08-05 Takeda Pharmaceutical Co Limited Compuesto heterociclico
TW202432109A (zh) 2022-10-31 2024-08-16 日商武田藥品工業股份有限公司 食慾素２型受體促效劑之給藥
WO2024116086A1 (en) 2022-11-30 2024-06-06 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JPWO2024128305A1 (es) 2022-12-16 2024-06-20
EP4680611A1 (en) 2023-03-16 2026-01-21 Takeda Pharmaceutical Company Limited Macrocyclic heterocycle compounds and use thereof
JP2026518313A (ja) 2023-06-01 2026-06-04 ハー・ルンドベック・アクチエゼルスカベット スピロ大環状オレキシン２受容体アゴニスト
TW202502342A (zh) * 2023-06-02 2025-01-16 日商武田藥品工業股份有限公司 食慾素２受體促效劑用於改善睡眠期間之呼吸功能的用途
CN122374291A (zh) 2023-12-12 2026-07-10 爱杜西亚药品有限公司 作为食欲素受体调节剂的芳基砜及砜酮衍生物
WO2025132542A1 (en) 2023-12-19 2025-06-26 Idorsia Pharmaceuticals Ltd Macrocyclic orexin agonists
GB202404750D0 (en) 2024-04-03 2024-05-15 Bial Portela & Ca Sa Orexin receptor agonists
TW202547460A (zh) * 2024-04-04 2025-12-16 日商橘生藥品工業股份有限公司 取代磺醯胺化合物
TW202547576A (zh) * 2024-04-04 2025-12-16 日商橘生藥品工業股份有限公司 取代磺醯胺巨環狀化合物
WO2025224168A1 (en) 2024-04-24 2025-10-30 Idorsia Pharmaceuticals Ltd Aryl sulfone and sulfanone derivatives as orexin receptor modulators
WO2025229494A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2025229493A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Dosing of orexin type 2 receptor agonists
WO2025229495A1 (en) 2024-04-29 2025-11-06 Takeda Pharmaceutical Company Limited Heterocyclic compound
TW202608857A (zh) 2024-05-01 2026-03-01 日商武田藥品工業股份有限公司 用於１型發作性睡病（ｎｔ１）之食慾素受體２（ｏｘ２ｒ）促效劑
WO2026017128A1 (zh) * 2024-07-17 2026-01-22 江苏恩华药业股份有限公司 作为食欲素受体激动剂的环烯烃衍生物及其组合物和用途
KR20260012686A (ko) * 2024-07-18 2026-01-27 (주)셀트리온 신규한 오렉신 2 수용체 작용제 및 이의 용도
WO2026114911A1 (en) * 2024-11-27 2026-06-04 H. Lundbeck A/S Orexin 2 receptor agonists

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1028305A (en) 1911-03-04 1912-06-04 Nicholas King Turnbull Machine for remaking wire-drawing dies.
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
EP1194449B1 (en) 1999-06-28 2010-09-22 Oklahoma Medical Research Foundation Inhibitors of memapsin 2 and use thereof
WO2001008720A2 (en) 1999-07-30 2001-02-08 The Board Of Trustees Of The Leland Stanford Junior University Hypocretin and hypocretin receptors in regulation of sleep and related disorders
US7112566B1 (en) 1999-09-17 2006-09-26 The Regents Of The University Of California Systemic administration of Hypocretin-1
US6204245B1 (en) 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
AU2001251306A1 (en) 2000-04-04 2001-10-15 Siegel, Jerome M. Treatment of sleep disorders with hypocretin-1
EP1581648A2 (en) 2002-09-09 2005-10-05 Nura, Inc. G protein coupled receptors and uses thereof
US20080260744A1 (en) 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
ATE391727T1 (de) 2002-12-13 2008-04-15 Janssen Pharmaceutica Nv Verfahren zur identifikation von modulatoren des humanen orexin-2-rezeptors
HUP0304101A3 (en) * 2003-12-22 2008-10-28 Sanofi Aventis Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
UY30284A1 (es) 2006-04-14 2007-11-30 Abbott Gmbh & Amp Compuestos de ariloxietilamina apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3
AU2012200270A1 (en) * 2007-05-23 2012-02-09 Merck Sharp & Dohme Corp. Pyridyl piperidine orexin receptor antagonists
US20110053859A1 (en) 2007-10-10 2011-03-03 The U. S. Government Respresented by the Department of Veterans Affairs Methods to reduce the effects of sleep deprivation
MX2010009693A (es) 2008-03-05 2010-12-20 Paratek Pharm Innc Compuestos de monociclina y metodos de uso de la misma.
US8258163B2 (en) 2008-06-04 2012-09-04 Board Of Regents, The University Of Texas System Small-molecule agonists for type-2 orexin receptor
US9527807B2 (en) 2011-04-05 2016-12-27 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
TW201341380A (zh) * 2012-04-05 2013-10-16 Takeda Pharmaceutical 磺醯胺衍生物及其用途
BR112015007516A2 (pt) 2012-10-10 2017-07-04 Actelion Pharmaceuticals Ltd antagonistas do receptor de orexina que são derivados de [orto bi-(hetero-)aril]-[2-(meta bi-(hetero-)aril)- pirrolidin-1-il]-metanona
WO2014170343A1 (en) 2013-04-15 2014-10-23 Icm (Institut Du Cerveau Et De La Moelle Épinière) Depolarizing agents and nicotinic acetylcholine receptor modulators for treating dopaminergic-related disorders
WO2014198880A1 (en) 2013-06-14 2014-12-18 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
US20160250224A1 (en) 2013-09-24 2016-09-01 The Board Of Regents Of The University Of Texas System Orexin-control of bone formation and loss
WO2015073707A1 (en) 2013-11-15 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating heart failure with agonists of hypocretin receptor 2
SG11201604639YA (en) 2013-12-12 2016-07-28 Univ Tsukuba Sulfonamide derivative or pharmaceutically acceptable acid addition salt thereof
JP6552117B2 (ja) 2014-03-28 2019-07-31 国立大学法人 筑波大学 敗血症の予防治療剤
TW201613902A (en) * 2014-08-13 2016-04-16 Eolas Therapeutics Inc Difluoropyrrolidines as orexin receptor modulators
EP3029024A1 (en) 2014-12-02 2016-06-08 Ferrer Internacional, S.A. 2-(2-aminophenoxy)-3-chloronaphthalene-1,4-dione compounds having orexin 2 receptor agonist activity
WO2016133160A1 (ja) 2015-02-19 2016-08-25 国立大学法人筑波大学 スルホンアミド誘導体またはその薬学的に許容される酸付加塩
MX389771B (es) 2015-03-24 2025-03-20 Paratek Pharm Innc Compuestos de minociclina para biodefensas.
CA2989146A1 (en) 2015-06-12 2016-12-15 Board Of Regents, The University Of Texas System Sulfonamide derivative and pharmaceutically acceptable acid addition salt thereof
US10980755B2 (en) 2015-09-10 2021-04-20 The Regents Of The University Of California LRH-1 modulators
SG11201806429PA (en) 2016-02-04 2018-08-30 Takeda Pharmaceuticals Co Substituted piperidine compound and use thereof
JP6957598B2 (ja) 2017-03-08 2021-11-02 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
JP7012703B2 (ja) 2017-03-08 2022-02-14 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
US11319286B2 (en) 2017-08-03 2022-05-03 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
US10428023B2 (en) * 2017-08-03 2019-10-01 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JPWO2019112007A1 (ja) 2017-12-07 2020-12-24 国立大学法人 筑波大学 鎮痛薬による眠気の予防または治療薬
EP3816154B1 (en) 2018-06-29 2025-04-23 Takeda Pharmaceutical Company Limited Heterocyclic compound and application thereof
US11655241B2 (en) 2018-06-29 2023-05-23 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JP7379374B2 (ja) 2018-12-12 2023-11-14 武田薬品工業株式会社 複素環化合物
JP7408569B2 (ja) 2018-12-12 2024-01-05 武田薬品工業株式会社 複素環化合物
WO2020132269A1 (en) 2018-12-20 2020-06-25 KSQ Therapeutics, Inc. Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors
PE20211700A1 (es) 2019-01-31 2021-09-01 Takeda Pharmaceuticals Co Compuesto heterociclico y su uso
CA3128155C (en) 2019-01-31 2023-09-19 Pfizer Inc. 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2
US11098029B2 (en) 2019-02-13 2021-08-24 Merck Sharp & Dohme Corp. 5-alkyl pyrrolidine orexin receptor agonists
WO2020167701A1 (en) 2019-02-13 2020-08-20 Merck Sharp & Dohme Corp. Pyrrolidine orexin receptor agonists

Also Published As

Publication number Publication date
MX2021008241A (es) 2021-08-16
TWI832962B (zh) 2024-02-21
JP7253640B2 (ja) 2023-04-06
EP4578853A2 (en) 2025-07-02
CN118290408A (zh) 2024-07-05
US20250243157A1 (en) 2025-07-31
AU2020215380B2 (en) 2025-09-25
CN113395993B (zh) 2024-02-20
EA202192138A1 (ru) 2022-03-10
CO2021011188A2 (es) 2021-10-29
KR102882779B1 (ko) 2025-11-07
IL284073B1 (en) 2025-03-01
MY209784A (en) 2025-08-04
SG11202106791XA (en) 2021-07-29
US12404237B2 (en) 2025-09-02
CN118420600A (zh) 2024-08-02
IL284073A (en) 2021-08-31
AR117916A1 (es) 2021-09-01
CN118271297A (zh) 2024-07-02
US20250243156A1 (en) 2025-07-31
EP4578853A3 (en) 2025-09-03
JP2023078426A (ja) 2023-06-06
US20260092033A1 (en) 2026-04-02
SI3917616T1 (sl) 2025-08-29
HRP20250785T1 (hr) 2025-09-12
CN118271298A (zh) 2024-07-02
RS67170B1 (sr) 2025-09-30
TW202043196A (zh) 2020-12-01
US20240360080A1 (en) 2024-10-31
PE20211700A1 (es) 2021-09-01
EP3917616A1 (en) 2021-12-08
JP2022519331A (ja) 2022-03-22
AU2020215380A2 (en) 2021-08-19
CA3124536A1 (en) 2020-08-06
EP3917616B1 (en) 2025-06-11
US20200247747A1 (en) 2020-08-06
US12421188B2 (en) 2025-09-23
JP7502512B2 (ja) 2024-06-18
US20210276949A1 (en) 2021-09-09
FI3917616T3 (fi) 2025-07-24
US11028048B2 (en) 2021-06-08
LT3917616T (lt) 2025-08-11
ZA202106304B (en) 2023-06-28
ES3037650T3 (en) 2025-10-03
CN113395993A (zh) 2021-09-14
AU2020215380A1 (en) 2021-08-19
PL3917616T3 (pl) 2025-09-08
US12415782B2 (en) 2025-09-16
CL2021001973A1 (es) 2022-04-08
DK3917616T3 (da) 2025-07-21
PH12021551846A1 (en) 2022-05-23
US20250243158A1 (en) 2025-07-31
US20230040770A1 (en) 2023-02-09
KR20210121080A (ko) 2021-10-07
IL284073B2 (en) 2025-07-01
BR112021014180A2 (pt) 2021-09-21
PT3917616T (pt) 2025-08-28
CN118344346A (zh) 2024-07-16
HUE071890T2 (hu) 2025-09-28
WO2020158958A1 (en) 2020-08-06

Similar Documents

Publication Publication Date Title
ECSP20015818A (es) Compuesto heterocíclico y su uso
CL2021001973A1 (es) Compuesto heterocíclico y su uso.
DK3994236T3 (da) Carbonhydridsammensætning
ECSP18066138A (es) Inhibidores de la proteína quinasa 1 que interactua con el receptor
CO2018008705A2 (es) Compuestos de piperidina sustituido y su uso
MX2017005051A (es) Polipropileno heterofasico con equilibrio mejorado de rigidez/impacto.
EP4041284A4 (en) VARIANT OF IGF2 CONSTRUCTS
EP3869078A4 (en) SEAL STRUCTURE
AR110204A1 (es) Composición de recubrimiento de semillas
UY37410A (es) Antagonistas de trpv4
JP1711205S (ja) いす
DK3788912T3 (da) Stolearrangement
PY18111999A (es) Hidroxiisoxazolinas y derivados de estos
JP2019207083A5 (es)
JP2020012785A5 (es)
EP3931385A4 (en) NANOFIBER SURFACES
AR106382A1 (es) Composición adhesiva de poliuretano
CL2021002423A1 (es) Un novedoso compuesto derivado de alulosa
PY2027944A (es) Bencilfenil hodroxiisoxazolinas y análogos de éstas como nuevos agentes fungicidas.-
CL2019000572A1 (es) Compuesto de imida y uso del mismo.
JP2021101083A5 (es)
JP1704674S (ja) 缶
PL3818908T3 (pl) Końcówka do mebli
EP3983167C0 (en) LOW FRICTION SHIM
JP2020089637A5 (es)